| Lung cancer has been the most common cancer in the world, there is estimated to be 1.8 million new cases and 1.59 million deaths in 2012, and the disease is the most common cancer in men worldwide. NSCLC accounts for about 80% of all lung cancer, the majority of patients have been observed in the middle-late stage,5-year survival rate is low. Therefore, it is more important for the early diagnosis of NSCLC. Today, imaging examination is the main diagnostic tool in clinical work, but it is not suitable for large-scale screening work due to its high cost and radiation. So we are located in urgent need of convenient, low cost and noninvasive tools. Currently, the importance of non coding RNAs in oncology research has been widely concerned, and used as NSCLC tumor diagnostic markers, causing them to gain increased attention.We screened eleven serum non coding RNAs (miR-21, miR-197, miR-1254, miR-574-5p, miR-125b, miR-155, miR-30d, miR-24, miR-182, miR-485-5p and MALAT1) and tested their differential expression in the training set and validation set by qRT-PCR. We conducted diagnosis model based on five non coding RNA by risk scores analysis. ROC analysis was used to evaluate the diagnostic performance of the non coding RNA model. The result showed that the areas under the curves (AUCs) were 0.915 and 0.875 for the training set and validation set, respectively. The five non coding RNA risk scores were also associated with NSCLC progression, and its diagnostic efficiency was relatively high for stages of Ⅰ/Ⅱ/Ⅲ.Breast cancer is the most frequent cancer among women with 1.67 million new cases diagnosed and 522 thousand deaths in 2012. Many research has shown that the expression level of non coding RNA is not only different in lung cancer, but also changed in breast cancer. In order to find the molecular biomarker of breast cancer, we constructed a diagnosis model based on four non coding RNAs. The receiver operating characteristic (ROC) curve results showed that the areas under the curves (AUCs) were 0.960 and 0.968 for the training set and validation set, respectively. These data indicate that the model has higher diagnosis efficiency, sensitivity and specificity, and can serve as a convenient tool for BC diagnosis.Based on the results of the previous research, miR-574-5p showed abnormal expression in serum of breast cancer patients, and with sharp diagnosis effect, sensitivity and specificity. So, the miR-574-5p was selected for further analysis. We will further study the miR-574-5p expression in serum of breast cancer patients and breast cancer cells in this study, to investigate the mechanism of miR-574-5p in breast cancer. The results showed that the expression of miR-574-5p is different in control, fibroadenoma of breast and breast cancer, and we found that there were a significant upregulation in the breast cancer group. Migration test showed that miR-574-5p regulated the migration ability, and there was some correlation with B-myb and MALAT1. Snai3 is the target gene of miR-574-5p, Snai3 is involved in regulating the migration process. So, miR-574-5p may indirectly govern migration of breast cancer.The above results suggested as miR-574-5p has played a vital role in the development and migration of breast cancer, and provide a theoretical basis for the clinical diagnosis and treatment of breast cancer.Lung cancer is comprised of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for about 80% of all lung cancer, and include adenocarcinoma, squamous carcinoma, glands squamous carcinoma and large cell carcinoma. The majority of patients have been observed in the middle-late stage, so 5-year survival rate is low. Diagnosis effect of NSCLC is generally poor due to the lack of convenient and noninvasive tools. Therefore, it is more important for the early diagnosis of NSCLC. MicroRNAs (miRNAs) and long non coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) are subsets of non coding RNA, and both are used as NSCLC tumor diagnostic markers, causing them to gain increased attention.We first constructed a serum miRNA and MALAT1 non coding RNA panel and tested its diagnostic performance as an NSCLC biomarker. We tested the expression of 10 candidate miRNAs (miR-21, miR-197, miR-1254, miR-574-5p, miR-125b, miR-155, miR-30d, miR-24, miR-182, miR-485-5p) and MALAT1 in a training set (36 NSCLCs vs.36 controls) by quantitative reverse transcription polymerase chain reactions. The serum non coding RNA panel’s diagnostic efficiency was tested by risk score function. The panel was subsequently utilized to validate the diagnostic performance in a second validation sample set (120 NSCLCs and 71 controls). And through the analysis of risk score function, ROC and cluster to analyze the diagnosis model of NSCLC.In the training set, the expression of the five non coding RNAs (miR-21, miR-1254, miR-485-5p, miR-574-5p, and MALAT1) was obviously different between the NSCLC patients and healthy controls. Risk score analysis revealed that the five non coding RNA panel can distinguish NSCLC patient samples from controls. The receiver operating characteristic (ROC) curve results showed that the areas under the curves (AUCs) were 0.915 (95% confidence interval (CI) 0.853-0.978) and 0.875 (95% CI 0.819-0.930) for the training set and validation set, respectively. The five non coding RNA risk scores were also associated with NSCLC progression, and its diagnostic efficiency was relatively high for stages of Ⅰ/Ⅱ/Ⅲ. In conclusion, these data indicate that the five non coding RNA panel can serve as a convenient tool for early NSCLC diagnosis.Conclusions:we first built a diagnosis model based on several serum miRNAs and a long non coding RNA MALAT1, with relatively high sensitivity and specificity. So, this model can be used as a noninvasive biomarker for the diagnosis of NSCLC.Breast cancer (BC) is the leading disease of women that seriously threaten their life and health, its incidence is increasing, and becoming more and more younger. The prognosis of breast cancer patients is strongly related to the stage of the disease. Therefore, it is essential that breast cancer is diagnosed and treated at the earliest stages. Mammography, ultrasound, magnetic resonance and nuclear medicine are utilized to test breast cancer. However, the high cost and bigger radiation of imaging examination does not apply in respect of work for early breast cancer detection. So, more sensitive and more specific detection assays tools are needed that avoid unnecessary imaging test. Non coding RNA assay of serum offers a noninvasive and cheaper screening approach to examine high-risk individuals.We first constructed a serum miRNA and MALAT1 non coding RNA panel and tested its diagnostic performance as a BC diagnosis biomarker. We tested the expression of 11 candidate miRNAs and MALATl in a training set (30 NSCLCs vs.30 controls) by quantitative reverse transcription polymerase chain reactions, miRNA-21, let-7a, miRNA-574-5p, miRNA-155, miRNA-10b, miRNA-181b, miRNA-1254, miRNA-196a, miRNA-205, miRNA-195。 The serum non coding RNA panel’s diagnostic efficiency was tested by risk score function. The panel was subsequently utilized to validate the diagnostic performance in a second validation sample set (128 BCs and 77 controls).In the training set, the expression of the four non coding RNAs (let7a, miR-155, miR-574-5p and MALAT1) was obviously different between the BC patients and healthy controls. Risk score analysis revealed that the four non coding RNA panel can distinguish BC patient samples from controls. The receiver operating characteristic (ROC) curve results showed that the areas under the curves (AUCs) were 0.960 (95% (CI) 0.864-1.000) and 0.968 (95% CI 0.903-0.985) for the training set and validation set, respectively. Moreover, the expression of the four non coding RNAs was obviously different in the normal control group, the fibroadenoma of the breast group and breast cancer group. The three non coding RNA (let-7a、miR-155 and miR-574-5p) panel can distinguish the fibroadenoma of breast samples from controls, AUC was 0.987. And miR-155、miR-574-5p and MALAT1 panel can distinguish breast cancer samples from fibroadenoma of breast samples, AUC was 0.959. And the expression of the four non coding RNAs was also obviously changed in preoperative and postoperative. And we found that miR-155 is greater sensitivity in the research of beast cancer before and after chemotherapy.Conclusion, we first constructed a serum miRNAs and MALAT1 non coding RNA panel and tested its diagnostic performance as a BC diagnosis biomarker. These data indicate that the panel has higher diagnosis efficiency, sensitivity and specificity, and can serve as a convenient tool for early BC diagnosis.Breast cancer is the first common cancer and the second leading cause of cancer mortality in women. The development and progression of breast cancer are a multiple factors and complex process. The study of pathogenesis of breast cancer, will help us find the target genes for clinical diagnosis and treatment. This will improve the prevention and early diagnosis of breast cancer.MiRNA is a class of short, non codingendogenous RNAs. It has been showed that miRNA had abnormal expression in a variety of tumor. Based on the results of the second part, miR-574-5p showed abnormal expression in serum of breast cancer patients, and high diagnosis effect, sensitivity and specificity. So, the miR-574-5p was chosen for further analysis. We will further study the miR-574-5p expression in serum of breast cancer patients and breast cancer cells in this study, to investigate the mechanism of miR-574-5p in breast cancer.Methods:1、The quantitative real-time PCR reaction for analysing the expression of miR-574-5p in control, fibroadenoma of breast and breast cancer, and study the relationship between the expression and clinical factors.2、The transwell method was done to investigate the migration of breast cancer cell; and analyse the gene change in different dose of miR-574-5p.3、We predicted the target gene of miR-574-5p by the bioinformatics and detected the relationship between miR-574-5p and Snai3 in breast cancer patients’serum.Results:1. The results of qRT-PCR showed that the expression of miR-574-5p poses different expression in three groups. We found that there were a significant upregulation in the breast cancer group.2. MCF-7 cell transfected with the miR-574-5p mimic showed a significant reduction in the number of migration compared to control; but transfected with the miR-574-5p inhibitor showed a significant elevation. The differential expression of B-myb and MALAT1 was observed in both treatment groups.3. We predicted that Snai3 is the target gene of miR-574-5p, and there was negative correlation between miR-574-5p and Snai3 in breast cancer patients’serum.Conclusion:1. MiR-574-5p may have an important role in the development of breast cancer, and can be had in a wide application prospect in the clinical diagnosis of breast cancer.2. Migration test results in vitro showed that miR-574-5p regulated the migration ability, and there was some correlation with B-myb and MALAT1.3. Snai3 may be the target gene of miR-574-5p, Snai3 is involved in regulating the migration process. So, miR-574-5p may indirectly govern migration of breast cancer. |
PDF Full Text Request